每经AI快讯,2月2日,诺诚健华官微宣布,公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组,总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展,有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照,旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。 ICP-488是一种口服的...
Source Link每经AI快讯,2月2日,诺诚健华官微宣布,公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组,总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展,有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照,旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。 ICP-488是一种口服的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.